FierceBiotechOriginal article
{"a":[{"_":"Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s","$":{"href":"/biotech/metabolic-biotech-kalohexis-files-confidential-ipo-develop-glp-1-challenger","hreflang":"en"}}]}
IPO/OfferingPositive
AI Analysis
Summary
Kalohexis, a spinout of Endevica, has submitted a confidential IPO filing to fund the development of obesity and cancer cachexia treatments as a potential GLP-1 challenger.
Outcome Details
confidential IPO filing submitted
Importance:6/10
Sentiment:
0.60
IPOobesityGLP-1 competitorcancer cachexiaEndevica spinout
Read the original article
Published by FierceBiotech on July 7, 2026 10:22 AM